Natco Pharma gets warning letter from USFDA for Telangana plant

Natco Pharma on Tuesday said it has received a warning letter from the US health regulator for its Telangana-based manufacturing plant. The US Food and Drug Administration (USFDA) had issued eight observations under Form 483 after inspecting the company's Kothur-based formulation facility.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/bgwpt83
via gqrds

Comments

Popular posts from this blog

SC transfers PIL seeking implementation of law on mental health care to NHRC

Hospital-insurer conflict: Will latest circular by NMC help in reducing the pain of health insurance policyholders?

Over 9.19 crore hospital admissions facilitated under Ayushman Bharat since 2018